Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Celgene Corporation : Celgene Outlines Plan for New Growth Phase

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/07/2013 | 04:44pm EDT

--Celgene expects to double net product sales between 2013 and 2017

--Company outlines numerous milestones in 2013 for three "potential blockbuster" drugs

--Two late-stage trials for experimental psoriasis drug apremilast meet primary goals

(Updates with analyst comment in paragraph 10, updated stock price in paragraph 15.)

 
   By Joseph Walker 
 

Celgene Corp. (CELG) detailed its strategy to achieve $12 billion in product sales by 2017, twice what it expects this year, as it expands its core hematology franchise and builds out new product lines in cancer and psoriasis.

"We absolutely believe that the best days of Celgene are in front of us," Chief Executive Robert Hugin said at the J.P. Morgan Healthcare Conference in San Francisco. "We have the opportunity to accelerate growth, build out these new franchises and have great results over the next five years."

Mr. Hugin said Celgene has three "potential blockbusters" that will face key milestones this year, including an application to the Food and Drug Administration for its Abraxane to treat pancreatic cancer, one of the hardest-to-treat cancers. The drug is already approved in other types of cancer.

The company also expects to seek regulatory approval in the second half of this year for its experimental drug apremilast to treat psoriasis, the severe skin rash disease. The drug met its primary goals in two late-stage studies, the company said Monday.

For 2012, the biopharmaceutical company said it now expects adjusted earnings of $4.90 a share and revenue of $5.5 billion, at the high end of its previous view of $4.85 to $4.90 a share and $5.45 billion to $5.55 billion, respectively.

Fourth-quarter and full-year results will be released Jan. 24.

The Summit, N.J., firm is a leader in treating blood cancer, and its hallmark drug Revlimid surpassed $1 billion in sales in the fourth quarter, the first time it has reached that mark in a single quarter, Mr. Hugin said. The company hopes to receive new approvals for Revlimid in the U.S., Europe and China this year.

The company's experimental drug Pomalyst could be the company's "next blockbuster," Mr. Hugin said, with a U.S. regulatory approval decision expected "in the next month or so" and in Europe by the end of 2013 to treat relapses of multiple myeloma.

For the new year, Celgene forecast adjusted earnings of $5.50 to $5.60 a share, in line with expectations of $5.56 from analysts polled by Thomson Reuters. It also predicted product sales, which account for nearly all the company's revenue, of $6 billion. Analysts project total revenue of $6.05 billion.

"We believe Celgene is re-emerging as a clean, earnings-driven growth stock as Abraxane's potential in pancreatic cancer becomes more fully appreciated and Revlimid gets back on track with European regulators," said Eric Schmidt, a Cowen & Co. analyst. "We expect Celgene's stock multiple to expand as a result."

Celgene expects Revlimid sales in 2013 to range from $4.1 billion to $4.2 billion, up about 9% to 12% year over year.

The company also reaffirmed its long-term financial targets for 2015 and forecast $13 to $14 a share in adjusted earnings and $12 billion in product sales for 2017.

Like other big drug makers, Celgene has been striving to find new treatments, as well as expand the uses of older ones, to drive growth. The company has been trying to expand uses of its blood-cancer treatment Revlimid to new diseases such as newly diagnosed multiple myeloma as well as non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

In October, the company said its third-quarter profit rose as it continued to see strong growth in Revlimid.

Celgene shares rose 4.4% to $85.73 on Monday. The stock is up 3.1% over the past three months.

-Ben Fox Rubin contributed to this article.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
09/12CELGENE : Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Thera..
BU
09/11Swiss Biotech Anokion Raises $40 Million in Series B Round
DJ
09/09CELGENE : Data from Ozanimod Clinical Development Program in Relapsing Forms of ..
BU
08/29CELGENE : Immatics and Celgene Enter Strategic Collaboration to Develop Novel Ad..
AQ
08/27Bristol-Myers Squibb Announces Agreement between Celgene and Amgen to Divest ..
AQ
08/27Amgen to Acquire Otezla for $13.4 Billion in Cash, or Approximately $11.2 Bil..
AQ
08/27Celgene, Bristol Clear Way For Merger -- WSJ
DJ
08/26Health Care Up Amid Deal Activity - Health Care Roundup
DJ
08/26Celgene and SRC Energy post gains while Pitney Bowes dips
AQ
08/26Wall Street bounces as trade temperature cools
RE
More news
Financials (USD)
Sales 2019 17 291 M
EBIT 2019 10 138 M
Net income 2019 6 470 M
Debt 2019 1 302 M
Yield 2019 -
P/E ratio 2019 11,3x
P/E ratio 2020 9,48x
EV / Sales2019 4,12x
EV / Sales2020 3,39x
Capitalization 69 932 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 99,87  $
Last Close Price 98,67  $
Spread / Highest target 21,6%
Spread / Average Target 1,21%
Spread / Lowest Target -13,9%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION53.85%69 882
JOHNSON & JOHNSON0.38%342 221
ROCHE HOLDING LTD.14.65%240 139
MERCK AND COMPANY7.98%211 257
PFIZER-16.38%201 883
NOVARTIS15.63%198 222